VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
View in:
PubMed
subject areas
Adult
Age Factors
Aged
Aged, 80 and over
Azacitidine
Benzimidazoles
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Follow-Up Studies
Hematologic Neoplasms
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
Male
Maximum Tolerated Dose
Middle Aged
Myelodysplastic Syndromes
Neoplasm Invasiveness
Neoplasm Staging
Patient Safety
Risk Assessment
Sex Factors
Survival Analysis
Treatment Outcome
authors with profiles
ZEEV ESTROV
MARINA KONOPLEVA
ALESSANDRA FERRAJOLI
GUILLERMO GARCIA-MANERO
WILLIAM G WIERDA
ELIAS JOSEPH JABBOUR
GAUTAM BORTHAKUR
TAPAN MAHENDRA KADIA
HAGOP M KANTARJIAN